Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 47 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H2 2016', provides in depth analysis on Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted pipeline therapeutics. 

The report provides comprehensive information on the Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) 
- The report reviews Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6
Global Markets Direct Report Coverage 6
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) Overview 7
Therapeutics Development 8
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Products under Development by Stage of Development 8
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Products under Development by Therapy Area 9
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Products under Development by Indication 10
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Products Glance 11
Early Stage Products 11
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Products under Development by Companies 12
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Therapeutics Assessment 15
Assessment by Monotherapy/Combination Products 15
Assessment by Mechanism of Action 16
Assessment by Route of Administration 17
Assessment by Molecule Type 18
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Companies Involved in Therapeutics Development 19
Amgen Inc 19
Astellas Pharma Inc 20
Aurigene Discovery Technologies Ltd 21
Beijing Hanmi Pharmaceutical Co Ltd 22
Genentech Inc 23
Merck & Co Inc 24
Rigel Pharmaceuticals Inc 25
TG Therapeutics Inc 26
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Drug Profiles 27
AS-2444697 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
CA-4948 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
ND-2110 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
ND-2158 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
ND-346 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
R-191 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Small Molecule to Inhibit BTK and IRAK4 for Autoimmune Disorders - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Small Molecule to Inhibit IRAK4 for Autoimmune Disorders - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Small Molecules to Inhibit Interleukin-1 Receptor Associated Kinase-4 for Arthritis, Inflammation and Oncology - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Small Molecules to Inhibit IRAK-4 for Inflammation - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Small Molecules to Inhibit IRAK4 for Immunology and Oncology - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Small Molecules to Inhibit IRAK4 for Inflammatory Diseases - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Dormant Projects 40
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Featured News & Press Releases 41
Apr 12, 2016: Rigel Announces Presentation on preclinical research project R191 at Upcoming American Association of Cancer Research (AACR) Conference 41
Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CA-4948 at AACR Annual Meeting 41
Nov 08, 2015: Curis Collaborator Aurigene Presents Preclinical Data From Oral Small Molecule IRAK4 Program at AACR-NCI-EORTC International Conference 42
Apr 20, 2015: TG Therapeutics Presents Pre-clinical Data on IRAK4 Compounds at the American Association for Cancer Research Annual Meeting 42
Apr 18, 2015: Aurigene to Present its IRAK-4 Inhibitors Programs at AACR 2015 42
Apr 14, 2015: Curis Announces Presentation of Data From IRAK-4 Program at AACR Annual Meeting 43
Nov 12, 2012: Nimbus discovery presents preclinical data on highly selective IRAK4 inhibitors for the treatment of rheumatic diseases. 43
Nov 12, 2012: Nimbus discovery presents preclinical data on highly selective IRAK4 inhibitors for the treatment of rheumatic diseases. 44
Nov 07, 2011: Ligand Reports Positive Preclinical Data On IRAK4 Program At 2011 American College Of Rheumatology Annual Scientific Meeting 44
Mar 10, 2011: Nimbus Discovery unveils first of its kind drug discovery paradigm; announces seed round co-led by bill gates. 45

Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 (Contd..1) 14
Assessment by Monotherapy/Combination Products, H2 2016 15
Number of Products by Stage and Mechanism of Action, H2 2016 16
Number of Products by Stage and Route of Administration, H2 2016 17
Number of Products by Stage and Molecule Type, H2 2016 18
Pipeline by Amgen Inc, H2 2016 19
Pipeline by Astellas Pharma Inc, H2 2016 20
Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 21
Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2016 22
Pipeline by Genentech Inc, H2 2016 23
Pipeline by Merck & Co Inc, H2 2016 24
Pipeline by Rigel Pharmaceuticals Inc, H2 2016 25
Pipeline by TG Therapeutics Inc, H2 2016 26
Dormant Projects, H2 2016 40